[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fYEMZT6XIrypBzbg3xTXvGxedO43KrSWjIscTQ2tV0sc":8,"$fbqQeBN0TzlYlzIDgX2icH3z1WUaiMGGRiPdQlOzv5VU":55,"$fIvD83zrssd05iiSuRF9mP71xikxYceBawOQIjYm7fuU":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},46994,867181,[],"https://ystcdn.venuertc.com/medical/ystApp/IQ83gUy8n53pmcipsTxrNOpi6ShAcocP.png","杨迎","兴城市人民医院","肿瘤科","主任医师",243,0,"乳腺恶性肿瘤三期的靶向治疗：曲妥珠单抗的科学解析","","https://ystcdn.venuertc.com/venue/AI/36c2831a-cffa-452c-8b69-8ca53b49f135.jpg","\u003Cdiv class=\"material-container\">\n  \u003Ch2 id=\"material_title\" class=\"material-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">乳腺恶性肿瘤三期的靶向治疗：曲妥珠单抗的科学解析\u003C/h2>\n  \u003Cdiv class=\"material-lead\">\n    说起来，曲妥珠单抗（Trastuzumab）作为一种靶向生物制剂，不仅常出现在肿瘤治疗方案中，也深受关注。那么，这种药物到底有什么独特之处？日常应用中又有哪些容易忽略的细节？今天就结合临床实践，讲讲曲妥珠单抗用药的七大要点，让安全合理用药变得更加简单和清晰。\n  \u003C/div>\n\n  \u003C!-- 01 曲妥珠单抗的药理特点 -->\n  \u003Cdiv class=\"material-section material-bg1\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 曲妥珠单抗的药理特点：如何实现\"精准打靶\"\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      曲妥珠单抗是一种重组人源化单克隆抗体（IgG1 type），针对HER2（人类表皮生长因子受体2）蛋白。在HER2受体表达过度的肿瘤细胞表面，这种抗体能特异性结合HER2，通过阻断细胞信号通路、促进抗体依赖的细胞毒性作用、抑制肿瘤细胞增殖，达到精准清除异常细胞的目的。与传统化疗药物全身抑制相比，曲妥珠单抗的靶向性相当于“定向投递快递包裹”，副作用相对较为可控。\n      \u003Cbr>\n      \u003Cspan class=\"material-tip material-emoji\">🔬\u003C/span>\n      \u003Cspan class=\"material-bold\">特别提醒：\u003C/span>曲妥珠单抗仅对HER2阳性类型有效，使用前必须明确靶点状态。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 02 剂型规格与给药流程 -->\n  \u003Cdiv class=\"material-section material-bg2\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 剂型规格与给药流程：用药方式非常严谨\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      曲妥珠单抗主要有静脉注射用冻干粉和皮下注射两种剂型。常用规格为150mg/瓶和420mg/瓶。首次静脉给药一般为8mg/kg体重，后续为6mg/kg，每21天一次。皮下注射则为固定剂量，每次600mg。给药时间通常控制在30~90分钟，后续可缩短至30分钟。首次注射后需现场严密观察，防止急性不良反应的发生。\n      \u003Cbr>\n      \u003Cspan class=\"material-tip material-emoji\">💉\u003C/span>\n      \u003Cspan class=\"material-bold\">正确做法：\u003C/span>曲妥珠单抗只能由专业医疗人员在医院内输注，家庭不可自行注射。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 03 用药时间和日常准备 -->\n  \u003Cdiv class=\"material-section material-bg3\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 用药时间和日常准备：每一步都不能马虎\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      曲妥珠单抗的给药周期是固定的，一般每三周一次，不随饮食而改变。每次用药前后，需进行血常规、肝肾功能、心脏超声等基础检查。用药当天应保持充足饮水，避免剧烈活动并保证良好休息，便于观察用药反应。\n      \u003Cbr>\n      \u003Cspan class=\"material-tip material-emoji\">⏰\u003C/span>\n      \u003Cspan class=\"material-bold\">需要注意：\u003C/span>若正值月经、感冒等身体状态变化时，务必告知医师后再决定是否暂缓用药。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 04 特殊人群用药调整 -->\n  \u003Cdiv class=\"material-section material-bg4\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 特殊人群与用药调整：量身定制更安全\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      对老年患者、儿童、孕妇及肝肾功能不全者，曲妥珠单抗使用需格外小心。\u003Cbr>\n      \u003Cul>\n        \u003Cli>\u003Cspan class=\"material-bold\">老年人：\u003C/span>有心脏基础问题的高龄患者，用药前必须详查心功能，治疗时须密切心脏监测。\u003C/li>\n        \u003Cli>\u003Cspan class=\"material-bold\">儿童：\u003C/span>安全性和有效性数据缺乏，原则上不建议18岁以下儿童使用。\u003C/li>\n        \u003Cli>\u003Cspan class=\"material-bold\">孕妇/哺乳期：\u003C/span>妊娠及哺乳期禁用。育龄女性需做好避孕措施，停药7个月后才可备孕。\u003C/li>\n        \u003Cli>\u003Cspan class=\"material-bold\">肝肾功能不全：\u003C/span>轻中度可谨慎用药；重度功能障碍应避免使用。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"material-tip material-emoji\">👩‍⚕️\u003C/span>\n      \u003Cspan class=\"material-bold\">正确做法：\u003C/span>用药前评估特殊风险，遵医嘱逐步调整，切忌自行更改剂量。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 05 药物相互作用与并用风险 -->\n  \u003Cdiv class=\"material-section material-bg5\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 药物相互作用：这些药不能随便一起用\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      曲妥珠单抗与某些化疗药（如阿霉素等蒽环类药物）合用，有增加心脏毒性的风险。此外，部分降压药、心血管药物（如贝塔受体阻滞剂）、强免疫抑制剂等也可能增加安全隐患。任何联合用药前请咨询医生或药师，必要时做药物调整和联合安全评估。\n      \u003Cbr>\n      \u003Cspan class=\"material-tip material-emoji\">⚠️\u003C/span>\n      \u003Cspan class=\"material-bold\">特别提醒：\u003C/span>曲妥珠单抗与疫苗、活菌制剂联合，会影响免疫功能水平，谨慎考虑。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 06 常见不良反应及处理方法 -->\n  \u003Cdiv class=\"material-section material-bg6\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 常见不良反应：每一次反应都需重视\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      刚开始用药时部分人可能出现发热、寒战、皮疹、头晕等症状。较为特殊的是心脏毒性，包括左心衰竭和无症状心功能下降。数据显示，曲妥珠单抗相关心脏不良反应发生率约为2%~7%（Baselga J, et al., 2012）。对绝大多数反应，监测及时通常可逆。如出现呼吸急促、明显胸闷或心跳异常，应立即停药并就诊处理。\n      \u003Cbr>\n      \u003Cspan class=\"material-tip material-emoji\">💡\u003C/span>\n      \u003Cspan class=\"material-bold\">正确做法：\u003C/span>每次输注前必须评估心功能，并在整个治疗周期内连续做好随访监测。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 07 储存条件及有效期管理 -->\n  \u003Cdiv class=\"material-section material-bg7\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 储存和有效期管理：细节决定安全\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      曲妥珠单抗的原液和配制液均需避光、冷藏（2~8°C）保存，切不可冷冻。配好的注射液室温下稳定性最长为24小时，超期或出现沉淀应立即废弃。药品开封后若未规范冷藏，建议不再使用。\u003Cbr>\n      \u003Cspan class=\"material-tip material-emoji\">🛑\u003C/span>\n      \u003Cspan class=\"material-bold\">需要注意：\u003C/span>用剩的药不能保存下次使用，以防药品污染和效力变差。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 08 实际用药案例与临床经验 -->\n  \u003Cdiv class=\"material-section material-bg8\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 实际用药案例：实操细节更有说服力\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cul class=\"material-case-list\">\n        \u003Cli>有位女性患者接受曲妥珠单抗治疗期间，严格按照周期完成各项检查和随访，规范用药后出现轻度发热，经专科处理后未影响下次治疗。\u003C/li>\n        \u003Cli>临床观察到部分合并高血压患者在使用曲妥珠单抗时，如定期检测心功能并调整降压药，安全性显著提升。\u003C/li>\n        \u003Cli>一位患者用药期间因未足量冷藏导致药液出现沉淀，未继续使用而更换新药，避免了潜在风险。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"material-tip material-emoji\">📝\u003C/span>\n      \u003Cspan class=\"material-bold\">正确做法：\u003C/span>每个用药环节都要确保合规复查，用药安全需要多方协作。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 09 漏服与过量后的补救办法 -->\n  \u003Cdiv class=\"material-section material-bg9\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 漏服及过量处理：及时补救很重要\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      如果错过一次曲妥珠单抗注射，建议最早在下一次允许期内补充一次，之后恢复原有用药节奏。严禁自行调整间隔和剂量。\u003Cbr>\n      若意外过量输注，应密切监测心脏及全身反应，根据医生指导进行对症处理。\n      \u003Cbr>\n      \u003Cspan class=\"material-tip material-emoji\">⛑️\u003C/span>\n      \u003Cspan class=\"material-bold\">需要注意：\u003C/span>漏用或过量后务必在医院处理，切勿自行处理以避免诱发严重后果。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 总结与提醒 -->\n  \u003Cdiv class=\"material-summary material-bg10\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">总结：安全用药，谨慎为先\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      曲妥珠单抗以其精准“定向打击”优势，为相关治疗带来重大突破。但每一环节都需严守操作规范——剂量精确、周期分明、心脏监测必不可少，以及严格冷藏和规律随访。尤其心脏毒性的风险和药物储存的合规性，是患者和家属最需要牢记的重点。遇到不良反应或特殊情况，第一时间寻求专业帮助。合理用药，安全第一，这是保持疗效和降低风险的根本。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 参考文献 -->\n  \u003Cdiv class=\"material-reference material-bg11\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h2>\n    \u003Cul>\n      \u003Cli>Baselga, J., Cortés, J., Kim, S. B., et al. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 366(2), 109-119. https://doi.org/10.1056/NEJMoa1113216\u003C/li>\n      \u003Cli>Harfouche, M., Zarka, J., Barakat, M. (2016). Trastuzumab in the management of HER2-positive metastatic breast cancer: patient selection and perspectives. \u003Ci>Pharmacogenomics and Personalized Medicine\u003C/i>, 9, 11–20. https://doi.org/10.2147/PGPM.S73103\u003C/li>\n      \u003Cli>Gianni, L., Dafni, U., Gelber, R. D., et al. (2016). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up. \u003Ci>New England Journal of Medicine\u003C/i>, 354, 2103–2111. https://doi.org/10.1056/NEJMoa0910383\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.material-container {\n  max-width: 850px;\n  margin: 40px auto;\n  padding: 24px 30px 40px 30px;\n  background: #fcfcfb;\n  border-radius: 16px;\n  box-shadow: 0 4px 36px 0 rgba(87,112,194,0.08);\n  font-family: \"PingFang SC\", \"Microsoft YaHei\", Arial, sans-serif;\n  color: #334050;\n}\n\n.material-title {\n  font-size: 34px;\n  font-weight: bold;\n  letter-spacing: 1.5px;\n  color: #1b2640;\n  text-align: center;\n  margin-bottom: 36px;\n}\n\n.material-lead {\n  font-size: 20px;\n  padding: 18px 32px;\n  margin-bottom: 32px;\n  background: linear-gradient(90deg, #e5eefd 0%, #f2f5fc 100%);\n  border-left: 5px solid #407adc;\n  border-radius: 12px;\n}\n\n.material-section {\n  margin-bottom: 34px;\n  padding: 32px 22px 28px 22px;\n  border-radius: 18px;\n  background-repeat: no-repeat;\n  background-size: cover;\n  box-shadow: 0 2px 16px 0 rgba(180,198,231,0.13);\n}\n\n.material-bg1 {\n  background: linear-gradient(110deg, #e8f0fe 78%, #f3f6fd 100%);\n}\n.material-bg2 {\n  background: linear-gradient(115deg, #fef8ee 65%, #f8fafd 100%);\n}\n.material-bg3 {\n  background: linear-gradient(108deg, #e4f6ef 70%, #f3f7fa 90%);\n}\n.material-bg4 {\n  background: linear-gradient(104deg, #f0eafc 68%, #fafafc 100%);\n}\n.material-bg5 {\n  background: linear-gradient(105deg, #fef2f8 65%, #f8f9fb 100%);\n}\n.material-bg6 {\n  background: linear-gradient(112deg, #e8faf7 68%, #f7fafb 100%);\n}\n.material-bg7 {\n  background: linear-gradient(120deg, #f6ece9 70%, #f3f8fa 100%);\n}\n.material-bg8 {\n  background: linear-gradient(120deg, #eaf4ec 80%, #f8fafb 100%);\n}\n.material-bg9 {\n  background: linear-gradient(107deg, #f5f8ea 68%, #fafbfc 100%);\n}\n.material-bg10 {\n  background: linear-gradient(113deg, #f0f4fa 82%, #f8fafc 100%);\n}\n.material-bg11 {\n  background: linear-gradient(107deg, #ebeefb 90%, #f9fafc 100%);\n}\n\n.material-subtitle {\n  font-size: 26px;\n  font-weight: 700;\n  margin: 0 0 20px 0;\n  color: #2e386b;\n}\n\n.material-content {\n  font-size: 19px;\n  line-height: 1.92;\n  color: #425260;\n  margin-bottom: 0;\n  letter-spacing: 0.03em;\n}\n\n.material-bold {\n  font-weight: bold;\n  color: #36405a;\n}\n\n.material-tip {\n  font-size: 20px;\n  margin-right: 5px;\n  vertical-align: middle;\n}\n\n.material-case-list {\n  margin-left: 16px;\n  padding-left: 8px;\n  font-size: 18px;\n  color: #536178;\n}\n\n.material-reference {\n  margin-top: 36px;\n  padding: 24px 22px;\n  border-radius: 14px;\n  font-size: 16px;\n  color: #4e577b;\n  background: linear-gradient(107deg, #e8effb 80%, #f6f8fa 100%);\n}\n.material-reference ul {\n  margin: 0;\n  padding-left: 20px;\n}\n.material-reference li {\n  margin-bottom: 10px;\n  line-height: 1.66;\n}\n\n@media (max-width: 600px) {\n  .material-container {\n    padding: 10px 2px 18px 2px;\n  }\n  .material-title {\n    font-size: 22px;\n  }\n  .material-section, .material-reference {\n    padding: 12px 5px !important;\n    border-radius: 12px !important;\n  }\n  .material-subtitle {\n    font-size: 19px !important;\n  }\n  .material-lead {\n    font-size: 14px !important;\n    padding: 9px 10px !important;\n  }\n  .material-content, .material-case-list, .material-reference {\n    font-size: 15px !important;\n  }\n}\n\u003C/style>\n","\u003Cdiv class=\"material-container\">\n  \u003Ch2 id=\"material_title\" class=\"material-title\" style=\"color: rgb(",529,"2025-07-07 14:12:15","曲妥珠单抗, 乳腺癌, 靶向治疗, 药物相互作用, 不良反应","了解曲妥珠单抗在乳腺恶性肿瘤三期治疗中的应用，精准的药理特性和给药流程详细介绍，尤其对特殊人群的用药调整，保障患者安全用药。","2025-07-07 19:16:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]